The GLP-1 Revolution: Companies Beyond Eli Lilly and Novo Nordisk

Key Takeaways

* The GLP-1 market, projected to exceed $100 billion, is currently dominated by Eli Lilly ($810.6B market cap) and Novo Nordisk ($167.0B market cap), but over 20 other public and private companies are advancing competitive or complementary therapies.

* Next-generation approaches are rapidly evolving beyond single GLP-1 agonists to include oral formulations, dual/triple receptor agonists (GLP-1/GIP/glucagon), and novel non-GLP-1 mechanisms targeting hormones like amylin, activin, and leptin.

* Significant investment is flowing into companies with mid-to-late-stage clinical assets, such as Viking Therapeutics ($3.9B) and Altimmune ($427M), while others like Dexcom ($26.2B) and Abbott ($183.7B) are building adjacent markets in diagnostics and delivery.

* Severe manufacturing constraints for injectable therapies present a critical bottleneck, creating immediate opportunities for companies developing oral alternatives or innovative drug delivery technologies.

* The competitive landscape extends beyond weight loss efficacy to key differentiators like tolerability, muscle mass preservation, cardiovascular and renal benefits, and combination treatment strategies.

Introduction: The Vast Ecosystem Beyond the Giants

The narrative of the GLP-1 revolution has been written largely by two pharmaceutical titans: Eli Lilly and Novo Nordisk. With blockbusters like Mounjaro/Zepbound and Ozempic/Wegovy driving combined market capitalizations approaching $1 trillion, their dominance is undeniable. The market for these therapies is projected to soar well above $100 billion in the coming decade.

However, focusing solely on these two behemoths obscures a far more dynamic and expansive ecosystem. Beneath the surface, a diverse array of over two dozen public and private companies—from established device makers to clinical-stage biotechs—are innovating across the entire value chain of metabolic disease. They are pursuing next-generation drug candidates, novel mechanisms of action, and critical enabling technologies. This article moves beyond the headline-grabbing giants to map the broader competitive landscape, analyzing the companies, pipelines, and investment theses that will define the next phase of the GLP-1 era.

The GLP-1 Mechanism: A Foundation for Expansion

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the natural incretin hormone GLP-1. Their primary mechanism involves stimulating insulin secretion and suppressing glucagon release from the pancreas in a glucose-dependent manner, which improves glycemic control with a low risk of hypoglycemia. Crucially for obesity, they also slow gastric emptying and act on receptors in the brain’s hypothalamus to promote satiety and reduce appetite.

The clinical success of these drugs has validated the metabolic pathway, but it has also revealed its limitations and opportunities. Side effects like gastrointestinal distress can be significant, weight loss plateaus over time, and a notable portion of lost mass can be lean muscle. Furthermore, the requirement for subcutaneous injection presents adherence and manufacturing challenges. This understanding has become the launchpad for a wave of innovation aimed at improving upon the first-generation GLP-1 foundation.

The Incumbent Dominance: Lilly and Novo’s Fortress

The current market structure is a duopoly of unprecedented scale.

Company	Key GLP-1/Obesity Assets	2026 Market Cap	Strategic Position
Eli Lilly	Tirzepatide (Mounjaro®/Zepbound®) - GLP-1/GIP dual agonist	$810.6B	Leader in efficacy with dual agonist; building broad portfolio in obesity, NASH, and sleep apnea.
Novo Nordisk	Semaglutide (Ozempic®/Wegovy®) - GLP-1 agonist	$167.0B	First-mover with massive commercial scale; advancing next-gen CagriSema (GLP-1/amylin).

Lilly’s tirzepatide, a GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) dual agonist, has demonstrated superior weight loss efficacy to Novo’s semaglutide in head-to-head trials, cementing its best-in-class profile. Novo is responding with its own next-generation combination, CagriSema (semaglutide plus the amylin analog cagrilintide). Both companies are aggressively expanding capacity, but demand continues to outstrip supply, leaving the door open for competitors.

The Challengers: A Landscape of Public and Private Contenders

Beyond the giants, the field includes companies ranging from large-cap diversifiers to micro-cap speculations. The following table highlights key public companies with direct programs in GLP-1s, obesity, or closely related metabolic conditions.

Company	Market Cap	Core Metabolic Focus / Pipeline Asset	Stage / Differentiation
Viking Therapeutics	$3.9B	VK2735 (GLP-1/GIP dual agonist, oral & injectable)	Phase 2. Potentially best-in-class oral efficacy data.
Altimmune	$427M	Pemvidutide (GLP-1/glucagon dual agonist)	Phase 2. Notable fat loss with lean mass preservation.
Rhythm Pharmaceuticals	$5.7B	Setmelanotide (MC4R agonist) for rare genetic obesities	Commercial. Niche, genetics-focused approach.
Terns Pharmaceuticals	$6.0B	TERN-601 (oral GLP-1 agonist)	Phase 1. Pursuing oral small molecule.
Maze Therapeutics	$1.6B	MZE001 (oral activin receptor inhibitor)	Phase 2. Non-GLP-1 mechanism targeting muscle loss.
Corbus Pharmaceuticals	$149M	CRB-913 (oral CB1 inverse agonist)	Phase 1. Novel CNS-targeted mechanism.
vTv Therapeutics	$154M	TTP399 (oral glucokinase activator) for type 1 diabetes	Phase 3 (for T1D). Alternative diabetes mechanism.
Belite Bio	$6.1B	Tinlarebant (oral RBP4 antagonist) for metabolic disease	Phase 3 (for Stargardt). Exploring in broader metabolism.
MannKind Corp	$710M	Inhaled insulin & technosphere drug delivery platform	Commercial. Delivery expertise for peptides.
Lexaria Bioscience	$20M	DehydraTECH® platform for enhanced oral delivery	Preclinical. Enabling tech for GLP-1 peptides.

Note: This list is not exhaustive and focuses on public companies with declared metabolic pipelines.

Next-Generation Therapeutic Approaches

The race is no longer just about developing another injectable GLP-1 agonist. The competitive frontier has shifted to several distinct, more sophisticated strategies.

1. Oral GLP-1s: The convenience of a pill is a major unmet need. The challenge is achieving sufficient bioavailability and tolerability. Companies like Terns Pharmaceuticals (TERN-601) and Viking Therapeutics (oral VK2735) are pursuing oral small molecules. Viking’s Phase 2 data for its oral dual agonist showed weight loss competitive with early-stage injectable rivals, highlighting the potential of this modality.

2. Dual and Triple Agonists: Building on Lilly’s tirzepatide, the goal is to harness multiple hormonal pathways for synergistic effects.

GLP-1/Glucagon Agonists: Drugs like Altimmune’s pemvidutide aim to combine weight loss with increased energy expenditure via glucagon receptor activation. Early data suggests a favorable profile on body composition (fat loss vs. muscle loss).

GLP-1/GIP/Glucagon "Triple Agonists": Lilly and Novo have triple agonists in development, theorized to offer even greater efficacy.

3. Amylin and Other Hormone Combinations: Amylin is a satiety hormone co-secreted with insulin. Novo’s CagriSema (GLP-1 + amylin) is a leading combination candidate. Other companies are exploring combinations with leptin sensitizers or other metabolic hormones.

4. Non-GLP-1 Mechanisms: To address limitations like muscle wasting or to treat non-responders, companies are targeting entirely different pathways.

Activin/Myostatin Inhibition: Maze Therapeutics is developing MZE001 to block activin receptors, aiming to prevent the loss of lean muscle mass that can accompany rapid weight loss—a major differentiator.

MC4R Agonists: Rhythm Pharmaceuticals has commercialized setmelanotide for specific rare genetic obesities, proving the principle of melanocortin pathway modulation.

Other Novel Targets: Companies like Corbus Pharmaceuticals (CB1 inverse agonist) and iBio (using an AI platform) are exploring early-stage, novel mechanisms.

Pipeline Analysis: Identifying Late-Stage Catalysts

While many programs are in early discovery, several contenders are approaching late-stage inflection points.

Viking Therapeutics ($VKTX): Its injectable GLP-1/GIP agonist, VK2735, is in Phase 2 with strong efficacy data. The oral formulation’s Phase 2 data has positioned it as a leading oral candidate. Phase 3 trial designs and partnership discussions are key near-term catalysts.

Altimmune ($ALT): The Phase 2b MOMENTUM trial for pemvidutide (GLP-1/glucagon) is fully enrolled, with topline data expected in Q4 2024. Its body composition profile will be a major focus.

Rhythm Pharmaceuticals ($RYTM): A commercial-stage company, its growth hinges on expanding the label for setmelanotide into broader obesity populations, with ongoing Phase 3 trials.

Large-Cap Adjacencies: Vertex Pharmaceuticals ($115.2B), while focused on cystic fibrosis and pain, has a growing interest in metabolic disease. Its APOL1 program for kidney disease intersects with the renal protective benefits of GLP-1s.

Supply Chain and Manufacturing: The Critical Bottleneck

The overwhelming demand for injectable GLP-1s has exposed a severe global shortage of manufacturing capacity, particularly for the complex fill-finish process of pen injectors. This bottleneck is a strategic vulnerability for the incumbents and a tangible opportunity for others.

Oral Therapies as a Solution: Successful development of an effective oral GLP-1 would bypass the sterile injectable supply chain, representing a massive scalability advantage. This is a core part of the investment thesis for oral program developers.

Delivery Innovation: Private companies like Diasome Pharmaceuticals (liver-targeted delivery) and Arecor (formulation stabilization) are working on technologies that could improve existing therapies. MannKind Corp’s Technosphere® inhalation platform also offers an alternative delivery route for peptides.

CDMO Constraints: The strain on contract development and manufacturing organizations (CDMOs) benefits those with in-house manufacturing expertise or early, secured capacity.

Investment Implications: Mapping the Future Winners

The investment landscape extends far beyond a binary bet on Lilly vs. Novo. Several archetypes of potential winners are emerging:

The Best-in-Class Challenger: A company that can demonstrably beat the efficacy, tolerability, or convenience profile of the incumbents. Viking Therapeutics currently leads this category with its oral dual agonist data. Success in Phase 3 would make it a prime acquisition target or standalone competitor.

The Differentiated Mechanism Player: Companies that solve a key problem, like muscle wasting. Positive Phase 2 data for Altimmune’s pemvidutide on body composition or for Maze Therapeutics’ MZE001 on muscle preservation could carve out valuable market segments, either alone or in combination with GLP-1s.

The Enabling Technology Provider: Firms that improve the delivery, formulation, or monitoring of metabolic therapies. Dexcom ($26.2B) is already a winner in continuous glucose monitoring, which is used alongside these therapies. Companies like Lexaria Bioscience or private Diasome could be leveraged through partnerships.

The Adjacent Market Leader: Large caps leveraging their scale in related areas. Abbott ($183.7B) dominates in glucose monitoring (Freestyle Libre) and nutritional science, positioning it to benefit from the overall expansion of metabolic disease management.

Risks are substantial: clinical failure, inferior efficacy versus established giants, long-term safety surprises, and the sheer commercial and manufacturing muscle of Lilly and Novo. However, the market is vast enough to support multiple multi-billion-dollar products with distinct profiles. The most attractive investments are in companies with clear, near-term clinical catalysts, protected intellectual property, and a plausible path to differentiation.

Methodology

This analysis is based on the proprietary company database of BiotechTube, containing profiles of public and private biotechnology companies worldwide. The companies listed were filtered for those with active research or development programs in GLP-1 therapies, obesity, type 2 diabetes, or directly related metabolic mechanisms and enabling technologies. Market capitalization data for public companies is sourced from real-time financial feeds and reflects values as of the latest update. Pipeline stages and drug mechanisms are derived from company press releases, SEC filings, clinical trial registries (ClinicalTrials.gov), and scientific presentations. The competitive landscape assessment is based on a synthesis of this public data, analyst reports, and industry commentary.

Data and analysis provided by BiotechTube. Updated 2026-03-26.